Oncometabolite D-2-Hydroxyglurate Directly Induces Epithelial-Mesenchymal Transition and is Associated with Distant Metastasis in Colorectal Cancer

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Colvin, Hugh ^a   Nishida, Naohiro ^a   Konno, Masamitsu ^a   Haraguchi, Naotsugu ^a   Takahashi, Hidekazu ^a   Nishimura, Junichi ^a   Hata, Taishi ^a   Kawamoto, Koichi ^a   Asai, Ayumu ^a   Tsunekuni, Kenta ^a,b   Koseki, Jun ^a   Mizushima, Tsunekazu ^a   Satoh, Taroh ^a   Doki, Yuichiro ^a   Mori, Masaki ^a   Ishii, Hideshi ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b TAIHO PHARMACEUTICAL CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA-HYDROXYGLUTARATE; GLUTAMINE; GLUTARIC ACID DERIVATIVE; HISTONE; ISOCITRATE DEHYDROGENASE; TRANSCRIPTION FACTOR ZEB1; ZEB1 PROTEIN, HUMAN;

CACO-2 CELL LINE; COLORECTAL TUMOR; EPITHELIAL MESENCHYMAL TRANSITION; GENETICS; HCT 116 CELL LINE; HEK293 CELL LINE; HT-29 CELL LINE; HUMAN; METABOLISM; METASTASIS; MUTATION; PROMOTER REGION; TUMOR CELL LINE;

CACO-2 CELLS; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; EPITHELIAL-MESENCHYMAL TRANSITION; GLUTAMINE; GLUTARATES; HCT116 CELLS; HEK293 CELLS; HISTONES; HT29 CELLS; HUMANS; ISOCITRATE DEHYDROGENASE; MUTATION; NEOPLASM METASTASIS; PROMOTER REGIONS, GENETIC; ZINC FINGER E-BOX-BINDING HOMEOBOX 1;

EID: 84994477318     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep36289     Document Type: Article

References (47)

1. Torre, L. A. et al. Global cancer statistics, 2012. CA. Cancer J. Clin. 65, 87-108 (2015).
2. Kim, Y. W. & Kim, I. Y. The Role of Surgery for Asymptomatic Primary Tumors in Unresectable Stage IV Colorectal Cancer. Ann. Coloproctol. 29, 44-54 (2013).
3. Anwar, S., Peter, M. B., Dent, J. & Scott, N. A. Palliative excisional surgery for primary colorectal cancer in patients with incurable metastatic disease. Is there a survival benefit? A systematic review. Color. Dis. 14, 920-930 (2012).
4. Christofk, H. R. et al. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature 452, 230-233 (2008).
5. Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: The next generation. Cell 144, 646-674 (2011).
6. Pavlova, N. N. & Thompson, C. B. The Emerging Hallmarks of Cancer Metabolism. Cell Metab. 23, 27-47 (2016).
7. Hamabe, A. et al. Role of pyruvate kinase M2 in transcriptional regulation leading to epithelial-mesenchymal transition. Proc. Natl. Acad. Sci. USA. 111, 15526-15531 (2014).
8. Miyo, M. et al. Tumour-suppressive function of SIRT4 in human colorectal cancer. Br J Cancer 113, 492-499 (2015).
9. Yang, M., Soga, T. & Pollard, P. J. Oncometabolites: linking altered metabolism with cancer. J. Clin. Invest. 123, 3652-3658 (2013).
10. Haas, R. et al. Intermediates of Metabolism: From Bystanders to Signalling Molecules. Trends Biochem. Sci. 41, 460-471 (2016).
11. Dang, L. et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 462, 739-744 (2009).
12. Losman, J.-A. et al. (R)-2-hydroxyglutarate is sufficient to promote leukemogenesis and its effects are reversible. Science 339, 1621-1625 (2013).
13. Koivunen, P. et al. Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation. Nature 483, 484-488 (2012).
14. Xu, W. et al. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α -ketoglutarate-dependent dioxygenases. Cancer Cell 19, 17-30 (2011).
15. Figueroa, M. E. et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 18, 553-567 (2010).
16. Lu, C. et al. IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature 483, 474-478 (2012).
17. Wise, D. R. et al. Hypoxia promotes isocitrate dehydrogenase-dependent carboxylation of α -ketoglutarate to citrate to support cell growth and viability. Proc. Natl. Acad. Sci. USA. 108, 19611-19616 (2011).
18. Mullen, A. R. et al. Oxidation of alpha-ketoglutarate is required for reductive carboxylation in cancer cells with mitochondrial defects. Cell Rep. 7, 1679-1690 (2014).
19. Terunuma, A. et al. MYC-driven accumulation of 2-hydroxyglutarate is associated with breast cancer prognosis. J. Clin. Invest. 124, 398-412 (2014).
20. Wise, D. R. et al. Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction. Proc. Natl. Acad. Sci. USA. 105, 18782-18787 (2008).
21. Montrose, D. C. et al. Metabolic profiling, a noninvasive approach for the detection of experimental colorectal neoplasia. Cancer Prev. Res. (Phila). 5, 1358-1367 (2012).
22. Shim, E.-H. et al. L-2-Hydroxyglutarate: an epigenetic modifier and putative oncometabolite in renal cancer. Cancer Discov. 4, 1290-1298 (2014).
23. Intlekofer, A. M. et al. Hypoxia Induces Production of L-2-Hydroxyglutarate. Cell Metab. 22, 304-311 (2015).
24. Kalluri, R. & Weinberg, R. A. The basics of epithelial-mesenchymal transition. Journal of Clinical Investigation 119, 1420-1428 (2009).
25. Bleeker, F. E. et al. IDH1 mutations at residue p.R132 (IDH1(R132)) occur frequently in high-grade gliomas but not in other solid tumors. Hum. Mutat. 30, 7-11 (2009).
26. Ward, P. S. et al. Identification of additional IDH mutations associated with oncometabolite R(-)-2-hydroxyglutarate production. Oncogene 31, 2491-2498 (2012).
27. Lin, A.-P. et al. D2HGDH regulates alpha-ketoglutarate levels and dioxygenase function by modulating IDH2. Nat. Commun. 6, 7768 (2015).
28. Gupta, G. P. & Massagué, J. Cancer metastasis: building a framework. Cell 127, 679-695 (2006).
29. Kobayashi, T. et al. A novel serum metabolomics-based diagnostic approach to pancreatic cancer. Cancer Epidemiol. Biomarkers Prev. 22, 571-579 (2013).
30. Nishiumi, S. et al. A novel serum metabolomics-based diagnostic approach for colorectal cancer. PLoS One 7, e40459 (2012).
31. Shaul, Y. D. et al. Dihydropyrimidine accumulation is required for the epithelial-mesenchymal transition. Cell 158, 1094-1109 (2014).
32. Grassian, A. R. et al. Isocitrate dehydrogenase (IDH) mutations promote a reversible ZEB1/microRNA (miR)-200-dependent epithelial-mesenchymal transition (EMT). J. Biol. Chem. 287, 42180-42194 (2012).
33. DiNardo, C. D. et al. Serum 2-hydroxyglutarate levels predict isocitrate dehydrogenase mutations and clinical outcome in acute myeloid leukemia. Blood 121, 4917-4924 (2013).
34. Fathi, A. T. et al. Prospective serial evaluation of 2-hydroxyglutarate, during treatment of newly diagnosed acute myeloid leukemia, to assess disease activity and therapeutic response. Blood 120, 4649-4652 (2012).
35. Gross, S. et al. Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations. J. Exp. Med. 207, 339-344 (2010).
36. Ward, P. S. et al. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell 17, 225-234 (2010).
37. Zhang, W. et al. HIF-1α Promotes Epithelial-Mesenchymal Transition and Metastasis through Direct Regulation of ZEB1 in Colorectal Cancer. PLoS One 10, e0129603 (2015).
38. Herman, J. G. & Baylin, S. B. Gene silencing in cancer in association with promoter hypermethylation. N. Engl. J. Med. 349, 2042-2054 (2003).
39. Kats, L. M. et al. Proto-oncogenic role of mutant IDH2 in leukemia initiation and maintenance. Cell Stem Cell 14, 329-341 (2014).
40. IDH1 inhibitor shows promising early results. Cancer Discov. 5, 4 (2015).
41. Gao, J. et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci. Signal. 6, pl1 (2013).
42. Cerami, E. et al. The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data. Cancer Discov. 2, 401-404 (2012).
43. Liesenfeld, D. B. et al. Aspirin Reduces Plasma Concentrations of the Oncometabolite 2-Hydroxyglutarate: Results of a Randomized, Double-Blind, Crossover Trial. Cancer Epidemiol. Biomarkers Prev. 25, 180-187 (2016).
44. Cooper, K. et al. Chemoprevention of colorectal cancer: systematic review and economic evaluation. Health Technol. Assess. 14, 1-206 (2010).
45. Losman, J.-A. & Kaelin, W. G. J. What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer. Genes Dev. 27, 836-852 (2013).
46. Struys, E. A. et al. Mutations in the D-2-hydroxyglutarate dehydrogenase gene cause D-2-hydroxyglutaric aciduria. Am. J. Hum. Genet. 76, 358-360 (2005).
47. Gibson, K. M. et al. Stable-isotope dilution analysis of D- and L-2-hydroxyglutaric acid: application to the detection and prenatal diagnosis of D- and L-2-hydroxyglutaric acidemias. Pediatr. Res. 34, 277-280 (1993).